Mesoblast announces it entered into NDRA with CMS DHHS for Ryoncil

Mesoblast (MESO) announced that it has entered into the Medicaid National Drug Rebate Agreement, NDRA, with the U.S. Centers for Medicare & Medicaid Services, CMS, Department of Health and Human Services, DHHS, for Ryoncil, the first mesenchymal stromal cell, MSC, therapy approved by U.S. Food and Drug Administration, FDA, for any indication. The NDRA agreement with Mesoblast means that the U.S. Government now provides inpatient and outpatient access for a treatment course of Ryoncil to the approximately 40% of U.S. children covered by Medicaid who have steroid-refractory acute graft versus host disease, SR-aGvHD, the remainder being covered by private insurance. U.S. states have the option to immediately cover Ryoncil, with mandatory coverage commencing July 1, 2025. The first three children with SR-aGvHD will receive a course of Ryoncil commencing this week.